Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer - a systematic review

Fredrik Helland, Martine Hallin Henriksen, Oke Gerke, Marianne Vogsen, Poul Flemming Hoilund-Carlsen and Malene Hildebrandt
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 495;
Fredrik Helland
2Department of Nuclear Medicine Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Hallin Henriksen
2Department of Nuclear Medicine Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oke Gerke
2Department of Nuclear Medicine Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Vogsen
1Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Poul Flemming Hoilund-Carlsen
2Department of Nuclear Medicine Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malene Hildebrandt
2Department of Nuclear Medicine Odense University Hospital Odense Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 59 no. supplement 1 495

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 23, 2018.

Copyright & Usage 
© 2018

Author Information

  1. Fredrik Helland2,
  2. Martine Hallin Henriksen2,
  3. Oke Gerke2,
  4. Marianne Vogsen1,
  5. Poul Flemming Hoilund-Carlsen2 and
  6. Malene Hildebrandt2
  1. 1Odense University Hospital Odense Denmark
  2. 2Department of Nuclear Medicine Odense University Hospital Odense Denmark

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2018 to April 2025

AbstractFullPdf
May 2018900
Jun 20183300
Jul 20181300
Aug 2018500
Sep 2018300
Oct 2018500
Nov 20182100
Dec 20181100
Jan 2019700
Feb 20191000
Mar 2019600
Apr 20191400
Jul 2019700
Aug 2019200
Sep 2019900
Oct 2019700
Nov 2019400
Dec 2019100
Jan 2020300
Feb 2020900
Mar 20201800
Apr 2020900
May 2020300
Jul 2020500
Aug 20203600
Sep 20202100
Oct 2020700
Nov 20201300
Dec 20201000
Jan 2021300
Feb 2021700
Mar 20212500
Apr 20212900
May 2021900
Jun 2021100
Jul 20211600
Aug 20212500
Sep 20211700
Oct 20211500
Nov 20218400
Dec 20214100
Jan 20225200
Feb 20221500
Mar 20223300
Apr 20223000
May 20221900
Jun 2022100
Jul 2022100
Aug 2022300
Sep 2022200
Oct 2022200
Nov 2022100
Dec 2022200
Jan 2023500
Feb 2023100
Mar 2023500
Apr 2023100
May 2023100
Jun 2023500
Jul 2023100
Aug 2023300
Sep 2023200
Oct 2023200
Nov 2023200
Dec 2023400
Jan 2024500
Feb 2024500
Mar 2024200
Apr 2024300
May 2024600
Jun 2024500
Jul 2024400
Aug 2024400
Sep 2024300
Oct 2024100
Nov 2024300
Dec 2024100
Jan 2025100
Feb 2025500
Mar 2025400
Apr 2025300
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer - a systematic review
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer - a systematic review
Fredrik Helland, Martine Hallin Henriksen, Oke Gerke, Marianne Vogsen, Poul Flemming Hoilund-Carlsen, Malene Hildebrandt
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 495;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer - a systematic review
Fredrik Helland, Martine Hallin Henriksen, Oke Gerke, Marianne Vogsen, Poul Flemming Hoilund-Carlsen, Malene Hildebrandt
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 495;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Breast Cancer: Novel Tracers, Response Biomarkers, and Therapy

  • Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT
  • 68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study
Show more Breast Cancer: Novel Tracers, Response Biomarkers, and Therapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire